BUSINESS
Lilly launches Mounjaro KwikPen in India, matches vial pricing for diabetes and obesity
Each KwikPen contains four doses, designed for single-patient use, and is priced between Rs14,000 and Rs 27,500 per month depending on strength.
BUSINESS
Apollo Hospitals Q1FY26 net profit jumps 42% to Rs 433 crore
The company’s core healthcare services or hospital division contributed ₹2,935 crore in revenue, up 11%, with EBITDA at ₹718 crore.
BUSINESS
New rules, naming and shaming as cosmetics industry gets a regulatory makeover
The government has come out with more stringent regulations as there has been a proliferation of new players in the industry, which has lower entry barriers, is self-regulated and mostly relies on third-party contract manufacturers
BUSINESS
India’s weight-loss drug market hits Rs 606 crore; El Lilly's Mounjaro takes the lead
There has been a 27% YoY increase in sales of weight-loss drugs, especially after the launch of Mounjaro and Novo Nordisk's Wegovy, which are both once-in-a-week injections
BUSINESS
Biocon gears up to ride weight-loss drug boom to script next growth chapter
Managing director & CEO Siddharth Mittal says is de-risking supply chain as Trump tariffs loom. 'We’re scenario-mapping but there’s a limit to how much we can do,' he tells Moneycontrol
BUSINESS
Biocon posts Rs 31 crore net profit in Q1FY26
Operating revenue grew 15% YoY to Rs 3,942 crore, with EBITDA rising 19% to Rs 829 crore.
BUSINESS
Eris Lifesciences eyes Novo Nordisk’s exit to expand human insulin play in India
Eris is preparing for a “day-one” launch of semaglutide in India once the patent expires in March 2026.
BUSINESS
SCHOTT expands India footprint with first local production of syringe and cartridge glass tubing
German glassmaker bets on GLP-1 boom and pharma self-reliance with new facility in Gujarat
BUSINESS
Trump's tariff threats: Indian Pharma is ready with a multi-pronged defence strategy
Indian drugmakers are responding with geographic diversification, supply-chain resilience and acquisition of US assets to brace for a potential disruption despite the current exemption
BUSINESS
Indian pharma dodges Trump’s additional 25% tariff for now
Exemption tied to national security probe buys time, but Section 232 investigation keeps sector on edge
BUSINESS
Alembic Pharma’s tariff playbook: Cost cuts, complex pipeline and a supply chain armor
“Even if tariffs do come in at 5-10 percent, they can be absorbed. But anything above 25 percent could make high-volume, low-margin products unviable,” said Pranav Amin, Managing Director, Alembic Pharmaceuticals.
BUSINESS
Alembic Pharma’s June quarter profit grows 15 percent on strong US generics sales
The performance was driven by strong growth in the US generics business that saw a 13 percent year on year increase in sales.
BUSINESS
Eris Lifesciences’ profit rises 41 percent on year to Rs 125 crore, driven by domestic branded formulation growth
The company's performance was driven by robust growth in its domestic branded formulations (DBF) business and improved operating margins.
BUSINESS
Sanofi Consumer Healthcare reports 21% rise in Q2 net profit
BUSINESS
Pharma giant Eli Lilly opens strategic technology and innovation hub in Hyderabad
The US pharmaceutical giant has already hired 100 professionals and plans to expand its headcount to 1,500 in the coming years, focusing on roles in AI, automation, cloud computing, and software engineering.
BUSINESS
Aster DM-QCIL merger may complete by Q4FY26, synergies to add 10-15% to EBITDA over two years: Alisha Moopen
"The goal is micro market leadership," Alisha Moopen, Deputy Managing Director of Aster DM Healthcare, stated in a recent interview.
BUSINESS
Mankind Pharma net drops 17.4% YoY to Rs 445 crore in Q1FY26
Revenue from operations surged to ₹3,570 crore, driven by strong growth in both domestic and export businesses.
BUSINESS
Hospital chains to add 14,500 beds, spend up to Rs 32,000 crore by FY27, says ICRA
Occupancy rates are projected to remain resilient at 62–64% in FY26, while average revenue per occupied bed is expected to grow 6–8%
BUSINESS
Indian pharma exports not part of Trump's 25% tariff ambit
"The imports of drug formulations and active pharmaceutical ingredients (APIs) are currently excluded from this tariff, consistent with the April 2025 reciprocal tariff framework, where pharmaceuticals were explicitly exempted," said Maitri Sheth, Equity Research Analyst- Pharma Sector, Choice Broking.
BUSINESS
Abbott India reboots Digene: old-school antacid, new school vibe
The pharma firm is making over the famed antacid, with Digene Insta On The Go, a single-dose, water-free stick pack leading the change
BUSINESS
Burdened by over 29,000 compliances, healthcare sector seeks government intervention
A 'white paper' by the industry body NATHEALTH and EY India identifies fragmented oversight, duplicative licensing and outdated regulations as key bottlenecks stifling efficiency and innovation
BUSINESS
Dr Reddy's prioritises branded assets for strategic acquisitions: CFO Narasimham
Last year's acquisition of Haleon's global NRT business (excluding the US) for over Rs 5,000 crore, has 'exceeded' expectations, with the branded business set to expand to approximately 45 percent of its portfolio
BUSINESS
India-UK FTA set to boost pharma and medtech trade
The deal, which eliminates tariffs on most finished pharmaceutical products and medical devices, is expected to boost India’s exports to the UK valued at over $914 million grew 18% year-on-year (YoY) in FY24 . Imports from UK stood at $430.15 million with a YoY growth of 13%, according Exim data.
BUSINESS
Natco CEO says scouting for buyouts larger than Adcock to boost non-US revenue
Vice Chairman and CEO Rajeev Nannapaneni said the company is looking for another transaction, potentially as large or even larger than the Adcock deal to gain a wider geographical footprint and bring greater stability to core earnings.
